Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

REGN Regeneron Pharmaceuticals

Trading 02-04 09:30:39 EST

768.61

+9.43

+1.24%

High770.00	Low765.34	Vol7.50K
Open765.80	D1 Closing759.18	Amplitude0.61%
Mkt Cap80.78B	Tradable Cap79.40B	Total Shares105.10M
T/O5.74M	T/O Rate0.01%	Tradable Shares103.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"REGN","market":"US","secType":"STK","nameCN":"Regeneron Pharmaceuticals","latestPrice":768.61,"timestamp":1770215436213,"preClose":759.18,"halted":0,"volume":7495,"delay":0,"changeRate":0.012421296662188235,"floatShares":103302739,"shares":105099464,"eps":41.59414,"marketStatus":"Trading","change":9.43,"latestTime":"02-04 09:30:39 EST","open":765.8,"high":770,"low":765.34,"amount":5742224.5465,"amplitude":0.006138,"askPrice":770.8,"askSize":19,"bidPrice":763.03,"bidSize":144,"shortable":3,"etf":0,"ttmEps":41.59414,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770238800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":759.18,"dividendRate":0.00458,"preHourTrading":{"tag":"盘前","latestPrice":765,"preClose":759.18,"latestTime":"09:29 EST","volume":768,"amount":584485.632,"timestamp":1770215397091,"change":5.82,"changeRate":0.007666,"amplitude":0.025686},"postHourTrading":{"tag":"盘后","latestPrice":760.64,"preClose":759.18,"latestTime":"19:57 EST","volume":18318,"amount":13907322.964,"timestamp":1770166632681,"change":1.46,"changeRate":0.001923,"amplitude":0.00353},"volumeRatio":3.22391,"impliedVol":0.3333,"impliedVolPercentile":0.1992},"requestUrl":"/m/hq/s/REGN","defaultTab":"news","newsList":[{"id":"2608603683","title":"Regeneron meldet für das Gesamtjahr 2025 einen Anstieg des Anteils am Kollaborationsgewinn aus Dupixent- und Kevzara-Verkäufen auf 5,24 Mrd. USD mit einem Plus von 34 Prozent","url":"https://stock-news.laohu8.com/highlight/detail?id=2608603683","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608603683?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:10","pubTimestamp":1770214234,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDLQxgGf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1974910355.USD","LU2362541273.HKD","LU2468319806.SGD","LU0823434740.USD","BK4139","BK4588","LU2106854487.HKD","LU0889565916.HKD","LU0823434583.USD","LU1917777945.USD","LU0289739699.SGD","REGN","BK4585","LU0109394709.USD","LU0823416689.USD","LU0114720955.EUR","LU0882574055.USD","LU2089984988.USD","LU2237438978.USD","LU0058720904.USD","LU2362540622.SGD","LU2362541513.USD","LU2023250504.SGD","LU0053666078.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2608360354","title":"Regeneron reports FY Dupixent and Kevzara net product sales of USD 18.38 billion, up 26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608360354","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608360354?lang=en_us&edition=fundamental","pubTime":"2026-02-04 22:10","pubTimestamp":1770214234,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 04, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL8J4rQn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU2106854487.HKD","LU2362541513.USD","LU2468319806.SGD","REGN","LU0109394709.USD","LU0289739699.SGD","LU0058720904.USD","LU0053666078.USD","LU0823416689.USD","LU2237438978.USD","LU2362541273.HKD","LU0823434740.USD","LU2089984988.USD","BK4139","LU2362540622.SGD","LU2023250504.SGD","LU0114720955.EUR","BK4585","LU0823434583.USD","LU1974910355.USD","BK4588","LU0320765992.SGD","LU1917777945.USD","LU0882574055.USD"],"gpt_icon":0},{"id":"2608782674","title":"Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608782674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608782674?lang=en_us&edition=fundamental","pubTime":"2026-02-03 16:50","pubTimestamp":1770108633,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) and R...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-regeneron-regn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-regeneron-regn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","IE00BFXG1179.USD","LU1670711040.USD","LU2242646821.SGD","LU1868836757.USD","BK4139","LU0289739699.SGD","LU0889565916.HKD","BK4534","LU0321505868.SGD","BK4007","LU0128526141.USD","LU2106854487.HKD","LU0029874061.USD","IE00BSNM7G36.USD","LU0225771236.USD","LU2023250504.SGD","LU2237438978.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0267386448.USD","REGN","LU0320765992.SGD","HCSG","LU0456855351.SGD","LU2362541273.HKD","LU2125154935.USD","LU1868836914.USD","LU1917777945.USD","BK4137","LU1323610961.USD","LU1093756168.USD","LU1989771016.USD","LU2362540622.SGD","BK4559","LU1261432733.SGD","LU1291159041.SGD","LU1670710588.SGD","LU1868837136.USD","BK4581","LU2360032135.SGD","BMY","LU0096364046.USD","XLV","LU0868494617.USD","LU0058720904.USD","LU1032466523.USD","LU0237698245.USD","LU1571399168.USD","LABU"],"gpt_icon":0},{"id":"2608826721","title":"Evercore ISI Keeps Their Buy Rating on Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608826721","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608826721?lang=en_us&edition=fundamental","pubTime":"2026-02-03 16:46","pubTimestamp":1770108409,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov maintained a Buy rating on Regeneron yesterday and set a price target of $875.00. The company’s shares closed yes...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-regeneron-regn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-keeps-their-buy-rating-on-regeneron-regn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REGN"],"gpt_icon":0},{"id":"2608848769","title":"Does Modest 2025 Results and New EYLEA HD Data Shift the Bull Case for Regeneron (REGN)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2608848769","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608848769?lang=en_us&edition=fundamental","pubTime":"2026-02-03 09:24","pubTimestamp":1770081872,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals recently reported Q4 2025 and full-year 2025 results showing modest year-on-year revenue and earnings growth, alongside ongoing share repurchases totaling about US$1.51 billion under its 2025 buyback program.\nThe company is also preparing to share new long-term and primary clinical data for its ophthalmology franchise, including EYLEA HD, at the Angiogenesis meeting on February 7, 2026, highlighting how label expansions and dosing flexibility could influence use in...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/33715-main-header/1756202993919"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/does-modest-2025-results-and-new-eylea-hd-data-shift-the-bul","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/news/does-modest-2025-results-and-new-eylea-hd-data-shift-the-bul","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HD","LU0079474960.USD","LU0114720955.EUR","LU1974910355.USD","LU0320765992.SGD","LU0889565916.HKD","LU2461242641.AUD","IE00BWXC8680.SGD","LU1551013425.SGD","LU0823434583.USD","LU0354030438.USD","REGN","LU2106854487.HKD","BK4504","LU2361045086.USD","LU1162221912.USD","LU0238689110.USD","LU0823411888.USD","LU1989772923.USD","LU1069344957.HKD","LU0053666078.USD","LU2362540622.SGD","LU1093756325.SGD","LU0820561818.USD","LU0823434740.USD","LU0058720904.USD","SG9999001440.SGD","LU1496350502.SGD","LU0354030511.USD","LU2237438978.USD","LU0320765646.SGD","LU0942090050.USD","LU0820562030.AUD","LU1917777945.USD","LU1496350171.SGD","BK4567","LU1674673691.USD","LU1778281490.HKD","LU2362541513.USD","LU2362541273.HKD","IE00BZ1G4Q59.USD","LU0943347566.SGD","LU0868494617.USD","LU1236620750.USD","IE00BSNM7G36.USD","BK4585","BK4139","LU0234572021.USD","BK4550","BK4534"],"gpt_icon":0},{"id":"2608818275","title":"Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2608818275","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608818275?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:43","pubTimestamp":1770068580,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Regeneron Pharmaceuticals Inc.  rose 1.83% to $755.02 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.54% to 6,976.44 and the Dow Jones Industrial Average  rising 1.05% to 49,407.66.The stock's rise snapped a three-day losing streak.Regeneron Pharmaceuticals Inc. closed 8.05% below its 52-week high of $821.11, which the company achieved on January 9th.The stock outperformed some of its competitors Monday, as Amgen Inc.  rose 0.82% to $344.68, Moderna Inc.  fell 3.45% to $42.55, and Gilead Sciences Inc.  rose 0.66% to $142.89.Trading volume  remained 273,383 below its 50-day average volume of 965,957.Data source: Dow Jones Market Data, FactSet. Data compiled February 2, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["REGN"],"gpt_icon":0},{"id":"2608899228","title":"Regeneron 2026 Outlook Balanced With Dupixent Growth, Sanofi Collaboration, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2608899228","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608899228?lang=en_us&edition=fundamental","pubTime":"2026-02-03 01:51","pubTimestamp":1770054669,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals'  2026 is shaping up as a \"potentially balanced year,\" with Dupixent likely to continue strong growth and mid-year Sanofi  collaboration expected to contribute to revenue and EPS, RBC Capital Markets said.Dupixent revenue reached $4.94 billion in fiscal 2025, compared with the prior consensus of $4.67 billion, while Eylea generated $577 million, helped by label enhancements, the brokerage said in a Friday note.The investment firm noted that near-term pipeline drivers beyond Fianlimab are limited and that additional biosimilar entries could pressure the ophthalmology market. Fianlimab combined with cemiplimab first-line metastatic melanoma data is expected in H1 2026, with Regeneron targeting progression-free survival comparable to Opdulag.RBC also highlighted the expected repayment of Sanofi development fees, which could drive a roughly $2.2 billion increase in collaboration revenue and support EPS growth to $46.45.The firm said Regeneron's ongoing research pr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0289739699.SGD","BK4007","LU0882574055.USD","LU0889565916.HKD","LU2089984988.USD","BK4585","LU0114720955.EUR","LU0058720904.USD","LU0823416689.USD","REGN","LU2023250504.SGD","BK4588","LU0109394709.USD","SNYNF","LU0320765992.SGD","LU0053666078.USD","LU1917777945.USD","LU2468319806.SGD","LU2362541273.HKD","LU2362541513.USD","IE00BFXG1179.USD","LU0823434740.USD","LU2106854487.HKD","BK4139","LU1974910355.USD","LU2237438978.USD","LU2362540622.SGD","LU0823434583.USD","SNY"],"gpt_icon":0},{"id":"2608896111","title":"These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2608896111","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608896111?lang=en_us&edition=fundamental","pubTime":"2026-02-03 01:13","pubTimestamp":1770052418,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/02/50307600/these-analysts-revise-their-forecasts-on-regeneron-pharmaceuticals-after-q4-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU2023250504.SGD","LU2237438978.USD","LU1917777945.USD","LU0053666078.USD","LU2362540622.SGD","BK4588","LU0889565916.HKD","BK4139","LU0320765992.SGD","LU0289739699.SGD","LU0058720904.USD","LU2362541513.USD","LU2468319806.SGD","LU2106854487.HKD","LU0109394709.USD","LU0823434583.USD","REGN","LU2089984988.USD","LU2362541273.HKD","LU0882574055.USD","LU1974910355.USD","BK4585","LU0823416689.USD","LU0823434740.USD"],"gpt_icon":0},{"id":"2608898050","title":"Regeneron Pharma Is Maintained at Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2608898050","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608898050?lang=en_us&edition=fundamental","pubTime":"2026-02-02 23:34","pubTimestamp":1770046440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 02, 2026 10:34 ET (15:34 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","LU0109394709.USD","BK4588","LU2362540622.SGD","LU0889565916.HKD","REGN","LU0289739699.SGD","LU2237438978.USD","LU2362541273.HKD","BK4139","LU2362541513.USD","LU0320765992.SGD","LU0823434740.USD","LU0882574055.USD","LU0053666078.USD","LU0114720955.EUR","BK4585","LU1917777945.USD","LU2468319806.SGD","LU0823416689.USD","LU2089984988.USD","LU0823434583.USD","LU2106854487.HKD","LU0058720904.USD","LU1974910355.USD"],"gpt_icon":0},{"id":"2608860697","title":"Regeneron Pharma Is Maintained at Buy by Truist Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2608860697","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608860697?lang=en_us&edition=fundamental","pubTime":"2026-02-02 22:48","pubTimestamp":1770043680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/REGN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 02, 2026 09:48 ET (14:48 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","REGN","LU0058720904.USD","LU2468319806.SGD","BK4585","LU0320765992.SGD","LU0823416689.USD","LU2023250504.SGD","LU1974910355.USD","BK4139","LU0114720955.EUR","LU2089984988.USD","LU0289739699.SGD","LU0823434583.USD","LU2237438978.USD","LU0889565916.HKD","LU0109394709.USD","LU2106854487.HKD","LU1917777945.USD","LU2362541513.USD","LU0882574055.USD","LU0053666078.USD","LU2362540622.SGD","BK4588","LU0823434740.USD"],"gpt_icon":0},{"id":"2608864933","title":"Oppenheimer Raises Price Target on Regeneron Pharmaceuticals to $865 From $750, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2608864933","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608864933?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:34","pubTimestamp":1770039282,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals (REGN) has an average rating of overweight and mean price target of $870.46, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic resea","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OPY","REGN"],"gpt_icon":0},{"id":"2608786480","title":"Regeneron Pharmaceuticals : Oppenheimer Raises Target Price to $865 From $750","url":"https://stock-news.laohu8.com/highlight/detail?id=2608786480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608786480?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:25","pubTimestamp":1770038752,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nAZN4S7UZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739699.SGD","LU0823416689.USD","LU2468319806.SGD","LU0823434583.USD","BK4585","LU2023250504.SGD","LU0114720955.EUR","LU0320765992.SGD","LU2362540622.SGD","BK4139","REGN","LU2362541273.HKD","LU0058720904.USD","BK4588","LU2362541513.USD","LU0109394709.USD","LU0882574055.USD","LU0823434740.USD","LU0053666078.USD","LU0889565916.HKD","LU2106854487.HKD","LU2089984988.USD","LU2237438978.USD","LU1917777945.USD","LU1974910355.USD"],"gpt_icon":0},{"id":"2608861319","title":"Scotiabank Reaffirms Their Hold Rating on Regeneron (REGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2608861319","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608861319?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:57","pubTimestamp":1770037068,"startTime":"0","endTime":"0","summary":"In a report released today, Louise Chen from Scotiabank maintained a Hold rating on Regeneron, with a price target of $770.00. According to TipRank...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/scotiabank-reaffirms-their-hold-rating-on-regeneron-regn-blurbs-3?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/scotiabank-reaffirms-their-hold-rating-on-regeneron-regn-blurbs-3?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["REGN"],"gpt_icon":0},{"id":"2608866252","title":"Regeneron announces upcoming presentations at Angiogenesis annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2608866252","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608866252?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:20","pubTimestamp":1770034841,"startTime":"0","endTime":"0","summary":"Regeneron (REGN) Pharmaceuticals announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis annual ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regeneron-announces-upcoming-presentations-at-angiogenesis-annual-meeting-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regeneron-announces-upcoming-presentations-at-angiogenesis-annual-meeting-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0289739699.SGD","REGN","LU2023250504.SGD","LU0882574055.USD","LU0114720955.EUR","BK4139","LU0058720904.USD","LU0889565916.HKD","LU2468319806.SGD","LU2106854487.HKD","LU2362541513.USD","BK4588","LU2237438978.USD","LU0320765992.SGD","LU0053666078.USD","LU2362540622.SGD","LU1974910355.USD","LU2089984988.USD","LU0823434740.USD","BK4585","LU1917777945.USD","LU0109394709.USD","LU0823434583.USD","LU2362541273.HKD","LU0823416689.USD"],"gpt_icon":0},{"id":"2608866835","title":"FDA Approves Regeneron's EYLEA HD for Macular Edema Following Retinal Vein Occlusion","url":"https://stock-news.laohu8.com/highlight/detail?id=2608866835","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608866835?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:04","pubTimestamp":1770033855,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration  has approved EYLEA HD  Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion . The approval is based on data from the Phase 3 QUASAR trial, which met its primary endpoint at 36 weeks. EYLEA HD provides the first every-two-month treatment option for these patients, who previously required more frequent treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on February 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL5fLlfP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1974910355.USD","LU2237438978.USD","BK4588","LU0320765992.SGD","LU2089984988.USD","LU0289739699.SGD","LU0882574055.USD","BK4585","LU0823434740.USD","LU0823416689.USD","LU1917777945.USD","LU2106854487.HKD","LU0058720904.USD","LU2362541513.USD","REGN","LU0109394709.USD","LU0114720955.EUR","LU0053666078.USD","LU2468319806.SGD","LU0823434583.USD","LU2362541273.HKD","BK4139","LU0889565916.HKD","LU2362540622.SGD","LU2023250504.SGD"],"gpt_icon":0},{"id":"2608865057","title":"Regeneron price target raised to $950 from $850 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2608865057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608865057?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033644,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Chris Schott raised the firm’s price target on Regeneron (REGN) to $950 from $850 and keeps an Overweight rating on the shares. Th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regeneron-price-target-raised-to-950-from-850-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regeneron-price-target-raised-to-950-from-850-at-jpmorgan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BBT3K403.USD","LU2237443465.HKD","LU0208291251.USD","LU2237443382.USD","LU0238689110.USD","LU2756315318.SGD","BK4516","LU0211331839.USD","LU0106831901.USD","LU0048584097.USD","IE00BYXW3230.USD","LU0289739699.SGD","LU0640476718.USD","LU1244550494.USD","LU1280957306.USD","IE00BLSP4239.USD","LU0106261372.USD","LU0265550946.USD","LU0310799852.SGD","LU2357305700.SGD","LU1145028129.USD","LU0820561818.USD","IE00BDCRKT87.USD","LU0053666078.USD","LU0823434740.USD","LU2242649171.HKD","LU2430703095.HKD","LU2468319806.SGD","LU2362541273.HKD","LU0256863811.USD","LU0265550359.USD","IE00BWXC8680.SGD","LU0882574139.USD","REGN","LU0006306889.USD","LU1548497426.USD","LU2264538146.SGD","LU2237443978.SGD","LU2237443622.USD","LU0971096721.USD","LU1261432733.SGD","LU2430703178.SGD","BK4581","LU1720051017.SGD","IE00BFXG1179.USD","IE00B1BXHZ80.USD","LU2106854487.HKD","LU2462157665.USD","LU1496350502.SGD","LU1244550221.USD"],"gpt_icon":0},{"id":"2608886573","title":"Regeneron Unveils Positive Phase 3 Results for EYLEA HD in Retinal Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2608886573","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608886573?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033636,"startTime":"0","endTime":"0","summary":"Regeneron Pharmaceuticals Inc. announced that new clinical data from its ophthalmology portfolio will be presented at the Angiogenesis 2026 annual meeting on February 7, 2026. The presentations will include final 64-week results from the Phase 3 QUASAR trial in patients with retinal vein occlusion and full primary results from the Phase 3b ELARA trial evaluating EYLEA HD  Injection 8 mg in patients with wet age-related macular degeneration or diabetic macular edema. The ELARA trial data supported the approval of EYLEA HD as a monthly treatment option for patients requiring more frequent dosing, and results showed that patients switching from other anti-VEGF agents to EYLEA HD generally experienced improvements in visual acuity and anatomic control of retinal swelling. The most common adverse reactions reported with EYLEA HD included cataract, conjunctival hemorrhage, and increased intraocular pressure.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL3CPpZd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU0114720955.EUR","NDAQ","LU2023250504.SGD","SG9999014039.USD","IE00B64PRP62.GBP","LU2237438978.USD","LU1917777945.USD","LU0053666078.USD","LU2362540622.SGD","LU0314104364.USD","BK4588","LU0889565916.HKD","SG9999014021.USD","BK4139","IE00BGHQF748.EUR","LU0320765992.SGD","LU0289739699.SGD","LU2095319765.USD","LU0058720904.USD","LU2362541513.USD","LU2468319806.SGD","LU2106854487.HKD","LU0109394709.USD","LU0823434583.USD","REGN","LU2089984988.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2362541273.HKD","LU0882574055.USD","LU1974910355.USD","BK4585","IE00BKPKM429.USD","LU0823416689.USD","SG9999014013.SGD","LU0823434740.USD","LU2210149790.SGD"],"gpt_icon":0},{"id":"2608986529","title":"Eylea Hd® (Aflibercept) Injection 8 Mg Presentations at Angiogenesis 2026 Underscore Strength of Its Clinical Profile for the Treatment of Serious Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2608986529","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608986529?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033610,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY0HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0882574055.USD","LU0823416689.USD","LU2023250504.SGD","LU2089984988.USD","LU0114720955.EUR","LU2237438978.USD","LU0289739699.SGD","LU0889565916.HKD","BK4139","LU0823434583.USD","LU0053666078.USD","LU0823434740.USD","LU2468319806.SGD","LU1974910355.USD","LU0109394709.USD","LU2362541273.HKD","LU2362540622.SGD","REGN","LU2362541513.USD","LU0058720904.USD","LU1917777945.USD","LU0320765992.SGD","BK4585","BK4588","LU2106854487.HKD"],"gpt_icon":0},{"id":"2608978834","title":"Regeneron Pharmaceuticals Inc : TD Cowen Raises Target Price to $880 From $820","url":"https://stock-news.laohu8.com/highlight/detail?id=2608978834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608978834?lang=en_us&edition=fundamental","pubTime":"2026-02-02 12:58","pubTimestamp":1770008315,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YV1QI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","REGN","LU2362540622.SGD","LU0823416689.USD","LU0109394709.USD","LU2023250504.SGD","LU0823434583.USD","LU0114720955.EUR","LU0289739699.SGD","LU0320765992.SGD","BK4585","LU0823434740.USD","LU1917777945.USD","BK4588","LU0889565916.HKD","LU2362541513.USD","LU2106854487.HKD","LU0058720904.USD","LU2468319806.SGD","LU1974910355.USD","LU0053666078.USD","LU2089984988.USD","LU2237438978.USD","LU0882574055.USD","LU2362541273.HKD"],"gpt_icon":0},{"id":"2608883546","title":"Regeneron price target raised to $800 from $745 at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2608883546","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608883546?lang=en_us&edition=fundamental","pubTime":"2026-02-01 23:35","pubTimestamp":1769960123,"startTime":"0","endTime":"0","summary":"Wells Fargo raised the firm’s price target on Regeneron (REGN) to $800 from $745 and keeps an Equal Weight rating on the shares. The firm found the...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regeneron-price-target-raised-to-800-from-745-at-wells-fargo-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regeneron-price-target-raised-to-800-from-745-at-wells-fargo-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0868494617.USD","LU0289739699.SGD","BK4207","LU2361044865.SGD","LU0310800965.SGD","LU1363072403.SGD","LU0052756011.USD","LU0320765992.SGD","BK4588","LU0971096721.USD","LU0208291251.USD","LU0708994859.HKD","LU1974910355.USD","LU0640476718.USD","BK4504","LU0310799852.SGD","LU0310800379.SGD","LU0256863811.USD","LU0109394709.USD","LU0130517989.USD","LU1074936037.SGD","LU1917777945.USD","LU0070302665.USD","LU0058720904.USD","LU0823416689.USD","LU1280957306.USD","LU1814569148.SGD","LU2237438978.USD","LU2106854487.HKD","REGN","LU2362541273.HKD","LU2468319806.SGD","LU0889565916.HKD","LU0477156953.USD","LU0267386448.USD","LU0648001328.SGD","LU1894683348.USD","LU2023250504.SGD","LU0128525689.USD","LU0149725797.USD","LU1267930490.SGD","LU0683600562.USD","LU2362540622.SGD","LU1506573853.SGD","IE0002270589.USD","LU1267930573.SGD","LU0175139822.USD","LU1069347547.HKD","LU0787776722.HKD","LU0868494708.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regeneron.com","stockEarnings":[{"period":"1week","weight":-0.0156},{"period":"1month","weight":-0.0221},{"period":"3month","weight":0.1785},{"period":"6month","weight":0.3562},{"period":"1year","weight":0.1385},{"period":"ytd","weight":-0.0164}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.514286,"avgChangeRate":0.03675},{"month":2,"riseRate":0.428571,"avgChangeRate":0.085989},{"month":3,"riseRate":0.470588,"avgChangeRate":-0.044318},{"month":4,"riseRate":0.470588,"avgChangeRate":0.017191},{"month":5,"riseRate":0.628571,"avgChangeRate":0.057479},{"month":6,"riseRate":0.428571,"avgChangeRate":0.006745},{"month":7,"riseRate":0.657143,"avgChangeRate":0.052646},{"month":8,"riseRate":0.542857,"avgChangeRate":0.022877},{"month":9,"riseRate":0.457143,"avgChangeRate":0.023281},{"month":10,"riseRate":0.4,"avgChangeRate":-0.00141},{"month":11,"riseRate":0.542857,"avgChangeRate":0.046018},{"month":12,"riseRate":0.485714,"avgChangeRate":0.043803}],"exchange":"NASDAQ","name":"Regeneron Pharmaceuticals","nameEN":"Regeneron Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regeneron Pharmaceuticals,REGN,Regeneron Pharmaceuticals股票,Regeneron Pharmaceuticals股票老虎,Regeneron Pharmaceuticals股票老虎国际,Regeneron Pharmaceuticals行情,Regeneron Pharmaceuticals股票行情,Regeneron Pharmaceuticals股价,Regeneron Pharmaceuticals股市,Regeneron Pharmaceuticals股票价格,Regeneron Pharmaceuticals股票交易,Regeneron Pharmaceuticals股票购买,Regeneron Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regeneron Pharmaceuticals(REGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regeneron Pharmaceuticals(REGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction